Background Multiple blood transcriptional signatures have been proposed for identification of active and incipient tuberculosis. We aimed to compare the performance of systematically identified candidate signatures for incipient tuberculosis and to benchmark these against WHO targets.
Introduction
Identification of people at high risk of developing tuberculosis enables the delivery of preventive treatment for a disease that accounts for more deaths than any other infectious disease worldwide, with an estimated 10 million incident cases and 1·6 million deaths in 2017. 1 This approach represents a fundamental component of the WHO End TB strategy, aiming for a 95% reduction in tuberculosis mortality and 90% reduction in tuber culosis incidence by 2035. 2 However, these efforts are undermined by the poor positive predictive value of available prognostic tests for development of tuberculosis, which focus on the identification of a Tcellmediated response to myco bacterial antigen stimulation, as a surrogate for latent tuberculosis infection. 3, 4 These tests include the tuberculin skin test and interferonγ release assays (IGRAs), which have positive predictive values of 1-6% for incident tuberculosis over a 2year period. [4] [5] [6] [7] The poor predictive value of available diagnostics precludes precise delivery of preventive therapy, thus increasing costs and potential adverse effects, attenuating the effectiveness of prevention programmes, and reducing rollout of preventive treatment in limitedresource settings, where most tuberculosis cases occur.
Increasing recognition of the continuum of tuber culosis infection and disease has led to renewed interest in the incipient phase of tuberculosis. [8] [9] [10] Incipient tuberculosis is defined by WHO as the prolonged asymptomatic phase of early disease before clinical presentation as active disease, during which pathology evolves. 11 This definition encompasses the incipient and subclinical phases described elsewhere. 12 Tests that identify the incipient phase, between latent infection and active disease, might lead to improved positive predictive value for incident tuberculosis, while still offering an opportunity to prevent tuberculosisrelated morbidity and mortality and reduce onward transmission. 12 The need for better predictive biomarkers for incident tuberculosis has led to WHO producing a target product profile for incipient tuber culosis diagnostics, stipulating minimum sensitivity and specificity of 75% and optimal sensitivity and specificity of 90% over a 2year period. 11 These minimum criteria are based on achieving a positive predictive value of 5·8%, when assuming 2% pretest probability, to improve on the predictive ability of existing tests. 11 Multiple studies have shown changes in the host trans criptome in association with active tuberculosis, when compared with healthy controls or individuals with latent tuberculosis infection or other diseases. [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] Signatures have become more concise since the initial discovery of a 393gene signature of active tuberculosis, 13 making their translation to nearpatient diagnostic tests more achievable. Perturbation in the transcriptome has been found to predate the diagnosis of tuberculosis, 17, [24] [25] [26] sug gesting that transcriptional signa tures might offer an opportunity to diagnose incipient tuberculosis and potentially fulfil the WHO target product profile. However, independent validation of each signature is still limited to a small number of datasets. Which of the multiple candidate transcriptional signatures performs best for the identification of incipient tuberculosis or whether any signatures meet the WHO diagnostic accuracy benchmarks remains unclear.
To address these knowledge gaps, we aimed to critically assess the potential value of whole blood transcriptional signatures as biomarkers for incipient tuberculosis in practice.
Methods

Search strategy and selection criteria
We hypothesised that any biomarker that distinguishes incipient or active tuberculosis from healthy people might detect incipient disease. We therefore did a systematic review and individual participant data metaanalysis, in accordance with Preferred Reporting Items for a Systematic Review and Metaanalysis of Individual Participant Data standards, 27 to identify candidate concise
Research in context
Evidence before this study We did a systematic review using comprehensive terms for "tuberculosis", "transcriptome", "signature" and "blood", without language or date restrictions, on April 15, 2019. Multiple studies have identified perturbation in the transcriptome that predates clinical diagnosis of tuberculosis and have discovered and assessed performance of one or more signatures for diagnosis of incipient tuberculosis within individual datasets. A head-to-head evaluation of candidate signatures was done, but omitted key signatures, and compared diagnostic accuracy for incipient tuberculosis in only a single dataset over a 0-6-month period. No previous studies have directly compared the diagnostic accuracy of all candidate signatures in a patient-level pooled dataset. It was therefore unknown which signature performs best for diagnosis of incipient tuberculosis, or whether any meets WHO target product profile benchmarks (aiming for sensitivity ≥75% and specificity ≥75% over 2 years).
Added value of this study
To our knowledge, we did the largest direct comparison to date of the performance of whole blood transcriptional signatures for diagnosis of incipient tuberculosis. We tested 17 candidate mRNA signatures, identified through a comprehensive systematic review, in a pooled dataset of 1126 RNA sequencing samples from four countries. We show that a single transcript (BATF2) and seven other multi-transcript signatures, regulated by interferon signalling, perform with equivalent diagnostic accuracy for incipient tuberculosis. The accuracy of all eight signatures declined markedly with increasing intervals to disease. No signature met the minimum WHO target product profile parameters for incipient tuberculosis biomarkers over a 2-year period. In contrast, the eight best performing signatures met or approximated the minimum target product profile parameters over a 0-3-month period. Using a threshold derived from two SDs above the mean of uninfected controls to prioritise specificity, they achieved sensitivities of 47·1-81·0% and specificities of more than 90%, leading to positive-predictive values of 11·2-14·4% and negative-predictive values of more than 98·9%, when assuming 2% pre-test probability.
Implications of all the available evidence
Multiple transcriptional signatures perform with equivalent diagnostic accuracy for incipient tuberculosis. These biomarkers reflect short-term risk of tuberculosis and only exceed WHO benchmarks if applied to 3-6-month intervals. A screening strategy that incorporates serial testing on a 3-6-monthly basis among carefully selected target groups, such as recent case contacts, might be required for optimal implementation of these biomarkers.
whole blood transcriptional signatures for incipient or active tuberculosis and test their diagnostic accuracy for incipient tuberculosis in published whole blood trans criptomic datasets, in which blood sampling and longitudinal followup was done. We searched Medline and Embase on April 15, 2019, without language or date restrictions, using comprehensive terms for "tuberculosis", "transcriptome", "signature" and "blood", with screening of identified titles and abstracts done by two independent reviewers. We included candidate whole blood mRNA signatures discovered with a primary objective of diagnosis of active or incipient tuberculosis compared with controls who were either deemed healthy or had latent tuberculosis infection. We tested the performance of eligible signatures in published whole blood trans criptomic datasets where sampling before tuberculosis diagnosis was done and interval time to disease was available. The full search strategy, eligibility criteria, and screening procedures are outlined in appendix 1 (pp 2-3).
In preparation for this metaanalysis, we extended the followup of a previously published cohort of London tuberculosis contacts 26 by relinking the full cohort to national tuberculosis surveillance records (until Dec 31, 2017; median followup increased from 0·9 years [IQR 0·7-1·2] to 1·9 years [1·7-2·2]) held at Public Health England using a validated algorithm. 28 National tuberculosis surveillance records include all statutory national tuberculosis notifications. An additional 27 samples and individuals were also available for inclusion in our analysis. The full updated dataset for this study is available in ArrayExpress (accession number EMTAB6845). The London contacts study was approved by the UK National Research Ethics Service (reference 14/EM/1208). 26 No other ethical approvals were sought for this metaanalysis because all other included patient level datasets were depersonalised and publicly available.
Data analysis
Individuallevel RNA sequencing data were downloaded for eligible studies and processed (including correction of batch effects) as outlined in appendix 1 (p 3). Only samples obtained before the diagnosis of tuberculosis were included. Prevalent tuberculosis was defined as a tuberculosis diagnosis within 21 days of sample collection, as previously. 4 Incipient tuberculosis cases were defined as individuals diagnosed with tuberculosis more than 21 days after blood RNA sample collection. Culture confirmed and clinically or radio logically diagnosed pulmonary or extrapulmonary tuberculosis cases were included in the main analysis. Nonprogressors were defined as individuals who remained tuberculosisfree during followup. Nonprogressor samples with less than 6 months of followup from the date of sample collection were excluded owing to risk of outcome misclassification. Participants with prevalent tuberculosis and those who received preventive therapy were excluded. For studies with serial samples from the same individuals, serial samples were included provided that they met these criteria and that they were collected at least 6 months apart, because they were treated as independent samples in the primary analysis.
Scores were calculated for candidate signatures (using the authors' described methods) for each participant in the pooled dataset. For signatures that required recon struction of support vector machine or random forest models, we validated the reconstructed model against the original authors' model by comparing receiver operating characteristic curves in their original test dataset when possible. Using a predefined control population (including only participants with negative tests for latent tuberculosis infection among the pooled dataset), batch corrected signature scores were transformed to Z scores (by sub tracting the control mean and dividing by SD) to standardise scaling across signatures. 26 All analyses were done using R (version 3.5.1), unless otherwise specified. Receiver operating characteristic curves for each signature were plotted for a 2year time horizon. The area under the receiver operating characteristic curve (AUC) and 95% CI were calculated using the DeLong method. 29 Any data that was originally used to derive specific signatures were excluded from the pooled dataset used to test the performance of the relevant signature. Receiver operating characteristic curves and AUCs for separate study datasets were initially examined to assess the degree of between study heterogeneity. Because little heterogeneity was observed for all signatures, a onestage individual participant data meta analysis, assuming common diagnostic accuracy across studies, was done for the primary analysis. AUCs were directly compared in a pairwise approach using paired DeLong tests. 29 The best performing signature available from all samples in the pooled dataset was used as the reference for comparison with all other signatures; signatures with AUCs smaller than the reference and with p values of less than 0·05 were deemed inferior. Correlation between signature scores was assessed by use of Spearman rank correlation. Pairwise Jaccard similarity indices between signatures were calculated using lists of their constituent genes. Clustered cocorrelation and Jaccard index matrices were generated in Morpheus using average Euclidean distance. Upstream analysis of transcriptional regulation was done using Ingenuity Pathway Analysis (version 49932394) and visualised as network diagrams in Gephi (version 0.9.2), depicting all statistically overrepresented molecules predicted to be upstream of more than two target genes for clarity, to highlight the predicted upstream regulators shared by the constituents of the transcriptional signatures.
Receiver operating characteristic curves and AUCs were assessed for the best performing signatures, using prespecified intervals to tuberculosis from sample collection (<3 months, <6months, <1 year, and <2 years). Sensitivity and specificity for each of these time intervals were determined at predefined cutoffs for each signature, See Online for appendix 1
For Morpheus see https://software.broadinstitute. org/morpheus/ defined as a standardised score of two, representing the 97·7th percentile of the IGRAnegative control population assuming a normal distribution, as in previous work. 26 These estimates were used to model the estimated predictive values for incident tuberculosis across a range of pretest probabilities.
We did several sensitivity analyses. First, we restricted inclusion of tuberculosis cases to those with micro biological confirmation. Second, we included only one blood RNA sample per participant from studies that serially sampled by randomly sampling one blood sample per individual. Third, we examined sensitivity and specificity for the best performing signatures using cutoffs defined by the maximal Youden Index 30 to achieve the highest accuracy within each time interval. Fourth, we recomputed the receiver operating character istic curves using mutually exclusive time intervals to tuberculosis of 0-3, 3-6, 6-12, and 12-24 months for each curve excluding participants who had developed tuberculosis in an earlier interval. Finally, we did a twostage individual participant data metaanalysis to ensure consistency with the primary onestage analysis, as described in appendix 1 (p 3).
This study is registered with PROSPERO, number CRD42019135618.
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data interpretation, or writing of the report. The corresponding author had full access to all the data in the study and had final responsibility for the decision to submit for publication.
Results
643 unique articles were identified in the systematic review (appendix 1 p 4). Four RNA datasets (table 1) and 17 signatures (table 2) met the criteria for inclusion. The RNA datasets included the Adolescent Cohort Study (ACS) of South African adolescents with latent tuberculosis infection; 24 the Bill and Melinda Gates Foundation Grand Challenges 674 (GC674) household tuberculosis contacts study in South Africa, the Gambia, and Ethiopia; 25 a London tuberculosis contacts study; 26 and a Leicester tuberculosis contacts study. 17 All four eligible datasets were publicly available. The ACS and GC674 studies were nested casecontrol designs within larger prospective cohort studies, whereas the London and Leicester tuberculosis contacts studies were pro spective cohort studies, with RNA sequencing done for all participants. All four studies were done in HIV negative participants. The London tuberculosis contacts study included only baseline samples, whereas the ACS, GC674, and Leicester tuberculosis contacts studies included serial sampling. All four studies assessed participants for evidence of prevalent tuberculosis at enrolment through clinical evaluation, and the London and Leicester tuberculosis contacts studies also did chest Where multiple signatures were discovered for the same intended purpose and from the same training dataset, we included the signature with greatest accuracy, as defined by the area under the receiver operating characteristic curve in the validation data. Where accuracy was equivalent, we included the most parsimonious signature. †Anderson38 included 42 genes in the original, Huang11 had 13, Kaforou25 had 27, and Walter45 had 51 (genes not included in current models were either duplicates or not identifiable in RNA sequencing data). ‡For disease risk scores, the sum of downregulated genes was subtracted from the sum of upregulated genes. For unsigned sums and modified disease risk scores, genes were summed, irrespective of their direction of regulation. §Calculated using non-log-transformed data using model coefficients from original publication. ¶Required normalisation of the training and test sets. This was done for each gene by subtracting the mean expression across all samples in the dataset and dividing by the SD. ||Calculated using non-log-transformed counts per million data with trimmed mean of M-values normalisation, as per original description. **Modelling approach was not clear from the original description. We recreated this using two approaches: as a simple equation of gene pairs ((GAS6+SEPT4)-(CD1C+BLK)) and as an SVM using the four constituent gene pairs, as previously described. 35 Because the former approach achieved marginally better performance that was closer to the authors' original description in their test dataset, this was included in the final analysis. xrays. The GC674 study excluded participants with tuberculosis diagnosed within 3 months of enrolment, and ACS excluded those diagnosed within 6 months. However, participants who developed tuberculosis within these timeframes following serial sampling events were included. All four studies achieved maximal quality assessment scores (appendix 1 pp 5-6). A total of 1126 samples from 905 patients met our criteria for inclusion (appendix 1 p 7). These included 183 samples from 127 incipient tuberculosis cases, of which 117 (92%) were microbiologically confirmed. Eight (6%) of 127 tuberculosis cases were known to be extrapulmonary, without pulmonary involvement. Baseline characteristics of the study participants are shown in the appendix 1 (pp 8-9). Of note, a large proportion of participants in the London (112 [35%] of 324) and Leicester (86 [83%] of 103) contact studies were of South Asian ethnicity. Principal component analyses revealed clear separation of samples by dataset when including the entire transcriptome, selected genes comprising only the candidate signatures included in the analysis, and invariant genes, indicative of batch effects in the data due to technical variation in RNA sequencing. 36 These batch effects were eliminated after batch correction (appendix 1 p 10).
Samples included Study design Population
Setting HIV status Sampling
Follow-up duration and method
Tuberculosis case definition
RNA sequencing methods
Newcastle
Of the 17 identified signatures (table 2) , all were discovered from distinct publications, apart from Suliman4 and Suliman2, which were derived from different discovery populations within the same study. Five studies used existing published datasets for discovery, 14, 23, 26, 31, 33 and the remainder used novel data. Two signatures were discovered from paediatric popu lations. 19, 21 Four signature discovery datasets included HIVinfected and HIVuninfected participants, 14, 16, 19, 23 one signature was discovered in an exclusively HIVinfected population for the purpose of active case finding 20 and the remainder were discovered in HIVnegative populations. Four signatures were discovered with the intention of diagnosis of incipient tuber culosis. [24] [25] [26] The remaining 13 were discovered for diagnosis of active tuberculosis disease, of which five 14, 17, 21, 31, 33 targeted dis crimination of tuberculosis from other diseases in addition to discriminating people with tuberculosis from people who were healthy or with latent tuberculosis infection. Of the 17 included signatures, only three were not discovered through a genomewide approach. 18, 21, 33 Four signatures required reconstruction of support vector machine models, 24, 26, 31, 34 and one required reconstruction of a random forest model. 18 Our reconstructed models were validated against the authors' original descriptions by comparing AUCs in common datasets (appendix 1 p 11). The distribution of signature scores, stratified by study, before and after batch correction is shown in appendix 1 (p 12).
Our analysis initially suggested AUCs for the identification of incipient tuberculosis over a 2year period were smaller overall in the GC674 dataset than in the ACS dataset (appendix 1 pp 13-14). However, the distribution of tuberculosis events during followup differed between these studies (appendix 1 pp 8-9). Following stratification by interval to disease, similar AUCs were observed between studies, suggesting that interval to disease confounded the association between source study and AUC. Because little residual between study heterogeneity was observed and principal component analyses after batch correction showed no clustering by study (appendix 1 p 10), we did a pooled data analysis without further adjustment for source study as the primary analysis.
We omitted scores for the Suliman2, Suliman4, and Zak16 signatures for samples comprising their corres ponding training sets within the GC674 and ACS datasets, but included scores for these signatures for all other samples. The signature with the largest AUC for the identification of incipient tuberculosis over a 2year period tested in pooled data from all 1126 samples was BATF2 (AUC 0·74, 95% CI 0·69-0·78). BATF2 was therefore used as the reference standard for paired comparisons of the other 16 candidate signatures. We found that seven signatures had equivalent AUCs to BATF2: Suliman2 (AUC 0·77 [ 0·71-0·82]), Kaforou25 The eight signatures identified with equivalent performance showed moderate to high correlation, as defined by Spearman rank correlation (correlation coefficients 0·44-0·84; appendix 1 p 17). In contrast, Singhania20, Anderson38, Huang11, and Walter45 showed little correlation with any other signature. The correlation matrix dendrogram showed the closest associations between signatures identified by the same research group (appendix 1 p 17).
Spearman rank correlation and Jaccard Index had a weak positive association, suggesting that overlapping constituent genes might partially account for their correlation (appendix 1 p 17) . The 40 genes comprising the eight signatures with equivalent AUCs are shown in figure 1A . Upstream analysis predicted that interferon IFNG, IFNA, STAT1 (the canonical mediator of interferon [IFN] signalling), and tumour necrosis factor (TNF) were the strongest predicted transcriptional regulators of these constituent genes ( figure 1B; appendix 2) .
Scores for the eight best performing signatures, stratified by interval to disease, are shown in figure 2 and appendix 1 (p 18). AUCs of these signatures declined with increasing interval to disease (range 0·82-0·91 for 0-3 months vs 0·73-0·82 for 0-12 months; figure 3 ; appendix 1 p 15). Figure 4 shows the diagnostic accuracy of the eight best performing candidates using prespecified cutoffs of standardised score of two based on the 97·7th percentile of the IGRAnegative control population, stratified by interval to disease and benchmarked against positive predictive value estimates based on a pretest probability of 2%. At this threshold, test sensitivities over 0-24 months of the eight best performing signatures ranged from 24·7% (95% CI 16·6-35·1) for the Suliman2 signature to 39·9% (33·0-47·2) for Sweeney3, and corresponding specificities ranged from 92·3% (89·8-94·2) to 95·3% (92·3-96·9). In contrast, over a 0-3month interval, sensitivities ranged from 47·1% (26·2-69·0) for the Suliman4 signature to 81·0% (60·0-92·3) for the Sweeney3 signature, with corresponding specificities of 90·9% (88·9-92·6) to 94·8% (93·0-96·2). For each of the timepoints, the eight signatures had overlapping confidence intervals, and largely fell in the same positive predictive value plane (5-10% over 0-24 months vs 10-15% over 0-3 months).
On the basis of a pretest probability of 2% at the prespecified cutoffs, all eight best performing signa tures achieved a positive predictive value marginally above the WHO benchmark of 5·8% for a 0-24month period, ranging from 6·8% for Suliman2 to 9·4% for Kaforou25, with corresponding negativepredictive values of 98·4% and 98·6% (appendix 1 p 21). For the 0-3month period, positive predictive values ranged from 11·2% for Gliddon3 to 14·4% for Zak16, with corresponding negativepredictive values of 99·0% and 99·3% (appendix 1 p 21).
Sensitivities and specificities of the eight equivalent signatures using cutoffs defined by the maximal Youden index for each time interval were smaller than the minimum WHO target product profile criteria for a 0-24month period but met or approximated the minimum criteria over 0-3 months (appendix 1 pp 22-23). Restricting inclusion of incipient tuberculosis cases to those with documented microbiological confirmation and including only one blood RNA sample per participant (by randomly sampling) produced no significant change to the main results (appendix 1 pp [24] [25] . Reanalysis of the receiver operating characteristic curves using mutually exclusive periods of 0-3, 3-6, 6-12, and 12-24 months magnified the difference in performance between the intervals, with 
See Online for appendix 2 performance declining more markedly with increasing interval to disease (appendix 1 pp [26] [27] . AUCs in the 12-24month interval ranged from 0·60 (95% CI 0·50-0·70) to 0·67 (0·60-0·75) for the eight equivalent signatures. Finally, our twostage metaanalysis approach showed similar findings to the primary analysis (appendix 1 pp 28-29).
Discussion
To our knowledge, this is the largest analysis to date of the performance of whole blood transcriptional signatures for incipient tuberculosis. We showed that eight candidate signatures performed with equivalent diagnostic accuracy over a 2year period. These signatures ranged from a single transcript (BATF2) to 25 genes (Kaforou25). The accuracy of all eight signatures declined markedly with increasing intervals to disease. These signatures only marginally surpassed the WHO target positive predictive value of 5·8% over 2 years, assuming 2% pretest probability and using a cutoff of two standard scores. However, sensitivity at this cutoff was only 24·7-39·9%, missing most cases. No signature achieved the WHO target sensitivity and specificity of 75% or more over 2 years, even when using the cutoff with maximal accuracy. In contrast, using two standard scores cutoffs over a 0-3month period, the eight best performing signatures achieved sensitivities of 47·1-81·0% and specificities of more than 90%. This led to positivepredictive values of 11·2-14·4% and negative predictive values of more than 98·9%, when assuming 2% pretest probability, suggesting that the WHO target product profile can be achieved over shorter time intervals.
To achieve the WHO target product profile, a screening strategy that incorporates serial testing on a 3-6monthly basis might therefore be required for transcriptional signatures. Such a strategy, however, is unlikely to be feasible at a population level. Instead, highrisk groups, such as household contacts, could be targeted. However, even this approach will be challenging in high transmission settings, given the limited global coverage of contacttracing programmes. In lowtransmission, highresource settings, serial blood transcriptional testing for risk stratification over a defined 1-2year period might be more achievable, particularly among recent contacts or new entry migrants from hightransmission countries, for whom risk of disease is highest within an initial 2 year interval. 4, 26, 37 Integral to scaleup of the use of these biomarkers is translation of transcriptional measurements from genomewide approaches to the reproducible quantification of selected signature gene transcripts, with appropriately defined cutoffs. Although such targeted transcript quantification has been done for some signatures using PCRbased platforms, [23] [24] [25] 38 no signature platforms have been validated for implementation in a nearpatient or commercial assay. An additional challenge to implementation is the cost of these assays. This cost is likely to far exceed the US$2 target specified by the WHO target product profile for a nonsputum triage test for tuberculosis disease, 39 but might achieve the WHO target price to identify incipient tuberculosis for less than $100, using the price of IGRAs as an initial benchmark. 11 The fact that a number of different signatures show equivalent performance enables greater freedom for commercial development of this approach by overcoming restricted access to specific signatures protected by intellectual property rights and encouraging competition to drive down costs.
The eight signatures that achieved equivalent perfor mance were discovered with the primary intention of diagnosis of incipient tuberculosis, [24] [25] [26] or differentiating active tuberculosis from people who are healthy or with latent tuberculosis infection. [14] [15] [16] 23 Discovery popu lations for these eight signatures included adults or adolescents from the UK or subSaharan Africa, 15, 16, [23] [24] [25] [26] or a metaanalysis of microarray data from multiple studies, 14 including a minimum of 37 incipient or active tuberculosis cases. All eight signatures were discovered using genomewide approaches. In contrast, the nine signatures with inferior performance included two derived from studies in children, 19, 21 one from a study that prioritised discrimination of active tuberculosis from other bacterial and viral infections, 17 and one from a study that conducted active casefinding for tuberculosis among people living with HIV. 20 The differences in primary intended applications, which are reflected in the study populations used for biomarker discovery, might account for their inferior performance when evaluated solely for identification of incipient tuberculosis in a predominantly healthy, HIVnegative adult and adolescent population. The signatures with inferior performance also included three discovered in panels of preselected candidate genes, rather than a genomewide approach, 18, 21, 33 and four with only 6-24 tuberculosis cases in the discovery sets. [31] [32] [33] [34] These observations suggest that use of a genomewide approach and inclusion of adequate numbers of diseased cases should be considered during signature discovery to increase the likelihood of identifying generalisable signatures.
The eight best performing signatures were derived from the application of different computational approaches but showed moderate to high levels of cocorrelation, with the closest associations between signatures identified by the same research group. This finding likely reflects common discovery datasets and modelling approaches used within research groups. Overlapping constituent genes only partially accounted for correlation between signatures, suggesting that they reflect different dimensions of a common host response to infection with Mycobacterium tuberculosis. This hypo thesis was strongly supported by the identification IFN and TNF signalling pathways as statistically enriched upstream regulators of the genes across the eight signatures. Although these host response pathways are unlikely to be specific to tuberculosis, the application of these biomarkers for incipient tuberculosis mitigates against the limitations of imperfect specificity by focusing on asymptomatic individuals in whom the probability of other diseases is low. The timedependent sensitivity of the signatures suggests that the duration of the incipient phase of tuberculosis is typically 3-6 months. However, even within the less than 3month time interval, the sensitivity of the best performing transcriptional signatures ranged from 47·1-81·0%, indicating that the biomarkers might have imperfect sensitivity for incipient tuberculosis or that the incipient phase can progress very rapidly among a subset of cases. Each signature did exhibit an AUC of more than 0·5 for discrimi nating incipient tuberculosis from nonprogressors even 12-24 months after sampling, suggesting that the incipient phase might be more prolonged in some cases. These slowly progressive cases might reflect those in which the host response initially achieves mycobacterial control in dynamic host-pathogen interactions. 40 These findings are generally mirrored in proteomic and metabolomic data from similar cohorts. 41, 42 The strengths of this study include the size of the pooled dataset, including 1126 samples from 905 patients and 183 samples from 127 incipient tuberculosis cases. Individuallevel data were available for all four eligible studies, all of which achieved maximal quality assessment scores and were done in relevant target populations of either recent tuberculosis contacts or people with latent tuberculosis infection. This facilitated a robust analysis of the diagnostic accuracy of the candidate signatures, stratified by interval to disease. Additionally, we did a comprehensive systematic review and identified 17 candidate signatures. For each of these signatures, gene lists and modelling approaches were extracted and validated by independent reviewers. Moreover, for signatures that required model reconstruction, our models were crossvalidated against original models by comparing AUCs using the same dataset wherever possible. This approach facilitated a comprehensive, headtohead analysis of candidate signatures for incipient tuberculosis for the first time, ensuring that each headtohead comparison was done on paired data. This approach contrasts with a headtohead systematic evaluation that included only two of the eight best performing signatures in our analysis and compared performance for incipient tuberculosis in only one dataset over a 0-6month period. 35 Furthermore, our metaanalytic methods ensured a standardised approach to RNA sequencing data, which included an unbiased approach to batch correction, with unchanged distri butions of signature scores within each dataset following correction.
A weakness of our analysis is that we were unable to do subgroup analyses by age, ethnicity, or country, because the contributing studies largely defined these strata. There were no clear differences in performance by study, supporting the generalisability of the results. We were also unable to account for previous BCG vaccination status, although we anticipate that BCG coverage is likely to be very high among the study populations included. Additionally, having observed little heterogeneity between studies, we did a pooled analysis, assuming common diagnostic accuracy between studies. The precision of our estimates therefore might be slightly overstated and statistical tests might be anticonservative. However, sensitivity analysis using a twostage meta analysis approach with random effects yielded similar findings, supporting the robustness of our results. Likewise, treating serial samples as independent was anticonservative, but findings were similar in our sensitivity analysis taking only one sample per individual at random.
All included datasets were from subSaharan Africa and the UK, although a substantial proportion of Asian participants were included in the UK studies. No data were available for people living with HIV or children younger than 10 years, among whom different blood transcriptional perturbations might occur in tuberculosis. 8, 19 Prospective validation studies in other regions and among these specific target populations are needed and could be used to periodically update this metaanalysis to further increase generalisability. Only eight tuberculosis cases were known to be extra pulmonary, thus precluding assessment of diagnostic accuracy stratified by tuberculosis disease site. Additionally, most incipient tuberculosis cases were contributed from the African datasets, with 12 cases from the UK studies. Nevertheless, the UK studies were done in appropriate target populations of close contacts of tuberculosis index cases and were done as cohort studies, as opposed to the African casecontrol designs. High specificity for correctly identifying nonprogressors among contacts is a key attribute in improving positive predictive value compared with existing tests. Hence, these UK datasets were valuable additions to the pooled metaanalysis. Furthermore, when multiple signatures were discovered from the same discovery population and for the same purpose, we only included the best performing signature from the original study's validation set in our analysis. We therefore excluded a small number of worseperforming candidate signatures to prioritise a parsimonious list of the most promising candidates. The probability of these excluded signatures performing better than the included signatures is therefore negligible.
In summary, we show for the first time that eight transcriptional signatures, including a single transcript (BATF2), have equivalent diagnostic accuracy for identification of incipient tuberculosis. Performance appeared similar across studies, including partici pants from the UK and subSaharan Africa. Signature performance was highly timedependent, with lower accuracy at longer intervals to disease. A screening strategy that incorporates serial testing on a 3-6monthly basis among selected highrisk groups might be required for these biomarkers to surpass WHO target product profile benchmarks.
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